This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > News


December 2017

Medical Innovation and Brexit; Beyond Geographic Location.

The past month saw Holland edge a head to head battle with Italy to host the European Medicines Agency. The move from London to Amsterdam exposes the depth of impact of Brexit. Although some Brits may struggle with being European, in the medical world we are tied together with an umbilicus – from research to …

December 2017

OSTEBA. Basque Office for HTA – Bilbao – October 2017

The EuroScan International Network is a collaborative network of agencies and an association of individuals and institutions for the sharing of information and development of methods for the early identification of important emerging or obsolete health-related technologies. By improving data collection, the sharing of information, innovation and best practices, EuroScan’s approach can improve the use …

December 2017

The Newcastle Rare Disease Showcase – October 2017

  The conference began with an introduction to Findacure, which is a UK charity that builds the rare diseases community to drive research and develop treatments. It works towards empowering patients through online portal, webinars, patient workshops, peer mentoring and raising awareness. The conference threw light on rare diseases in the UK such as fibrodysplasia, …

November 2017

NHS Expo 2017

2017 saw over 5,000 delegates arrive in Manchester for the NHS England 2017 Expo

May 2017

Latest Pharmacological Technology Briefings Now Available

Our latest batch on pharmacological technologies in development is now available SQ HDM SLIT-tablet for house dust mite allergic asthma Pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy – first line Pembrolizumab (Keytruda) for endometrial carcinoma – second line Ipilimumab (Yervoy) for unresectable malignant melanoma …

Get Alerts